Haemonetics Corp. (NYSE: HAE) reported Q2 EPS of $0.65, $0.13 worse than the analyst estimate of $0.78. Revenue for the quarter came in at $170.6 million versus the consensus estimate of $170.4 million.

Affirms outlook.

Earnings Guidance